Gram Negative Bacterium (e.g., Escherichia Coli, Salmonella, Helicobacter, Etc.) Patents (Class 514/2.8)
-
Publication number: 20140010835Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: March 14, 2013Publication date: January 9, 2014Inventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schueler, Benjamin Wizel
-
Publication number: 20130345121Abstract: Provided herein are novel compounds and novel protected compounds that can be derived from polymyxin, including, e.g., polymyxin B1 and [Ile7] polymyxin B1. The novel compounds have antibacterial properties against a diverse range of gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin B. Also provided are antibacterial pharmaceutical compositions containing the novel compounds and novel protected compounds, as well as methods for preparing the antibacterial compounds and protected compounds.Type: ApplicationFiled: December 21, 2012Publication date: December 26, 2013Applicant: BioSource Pharm, Inc.Inventor: BioSource Pharm, Inc.
-
Patent number: 8614179Abstract: There is described a composition comprising a therapeutically active imidazole, and derivatives thereof, and an agent active on a bacterial cell surface selected from the group consisting of one or more of colistin, nisin, D-cycloserine, fosfomycin, fosfomycin trometamol, fosfomycin disodium and polymixin B, and derivatives thereof.Type: GrantFiled: July 17, 2009Date of Patent: December 24, 2013Assignee: E-Therapeutics PLCInventors: Malcolm Philip Young, Catherine Mary Thomas
-
Publication number: 20130336950Abstract: A material combination is configured to treat or prevent inflammatory and infectious diseases caused by fastidious anaerobic or facultative anaerobic microorganisms, such as bacteria or Candida sp. The material combination includes at least one antimicrobial peptide that can be activated by a reducing substance, and at least one reducing agent.Type: ApplicationFiled: August 19, 2011Publication date: December 19, 2013Inventors: Jan Wehkamp, Bjoern Schroeder, Eduard Stange
-
Patent number: 8603968Abstract: Cyclic peptides having a random alternation of L-?-aminoacyl residues and aza-?3-aminoacyl residues and their uses.Type: GrantFiled: October 8, 2008Date of Patent: December 10, 2013Assignees: Centre National de la Recherche Scientifique, Universite de Rennes IInventors: Mathieu Laurencin, Céline Zatylny-Gaudin, Joël Henry, Michéle Baudy Floc'H
-
Patent number: 8592367Abstract: The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.Type: GrantFiled: June 15, 2010Date of Patent: November 26, 2013Assignee: Centre National de la Recherche ScientifiqueInventors: Eva Kondorosi-Kuzsel, Peter Mergaert, Willem Van de Velde, Gergely Maroti, Attila Farkas, Attila Kereszt
-
Publication number: 20130310307Abstract: The invention provides a method of killing an infectious microbe by administering an effective amount of transferrin to an individual having a microbial infection, wherein the transferrin has microbicidal activity, thereby reducing survival of the infectious microbe in the individual. The invention also provides a method of prophylactically treating an individual to decrease the likelihood of contracting a microbial infection, comprising administering an effective amount of transferrin to an individual, wherein the transferrin has microbicidal activity, thereby decreasing the likelihood that the individual will contract a microbial infection. The invention still further provides a method of treating septicemia by administering an effective amount of transferrin to an individual in need thereof, thereby treating the individual.Type: ApplicationFiled: March 13, 2013Publication date: November 21, 2013Applicant: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTERInventors: Brad J. SPELLBERG, Lin LIN
-
Publication number: 20130288953Abstract: The inventors provide the use of a composition comprising an antimicrobial polypeptide comprising Blad or an active variant thereof to prevent or inhibit spoilage of a foodstuff by a microorganism. Also provided is a method of preventing or inhibiting spoilage of a foodstuff by a microorganism comprising administering to a foodstuff in need thereof an effective amount of a composition comprising an antimicrobial polypeptide comprising Blad or an active variant thereof.Type: ApplicationFiled: October 12, 2011Publication date: October 31, 2013Applicant: CONSUMO EM VERDE-BIOTENOLOGIA DAS PLANTAS S.A. (PT/PT)Inventors: Alexandra Manuela Lourenço Carreira, Sara Alexandra Valadas Da Silva Monteiro, Ricardo Manuel De Seixas Boavida Ferreira
-
Publication number: 20130288954Abstract: The inventors provide the use of a chelating agent and an antimicrobial agent that is effective against a plant pathogenic microorganism to inhibit the growth of and/or kill a plant pathogenic microorganism on a plant; the use of a chelating agent to increase the activity of an antimicrobial that is effective against a plant pathogenic microorganism; a method of inhibiting the growth of and/or killing a plant pathogenic microorganism comprising administering to a plant in need thereof a chelating agent and an antimicrobial agent that is effective against a plant pathogenic microorganism; and a method of increasing the activity of an antimicrobial that is effective against a plant pathogenic microorganism comprising using said antimicrobial with a chelating agent.Type: ApplicationFiled: October 12, 2011Publication date: October 31, 2013Applicant: CONSUMO EM VERE-BIOTECNOLOGIA DAS PLANTAS S.A. (PT/PT)Inventors: Alexandra Manuela Lourenço Carreira, Ricardo Manuel De Seixas Boavida Ferreira, Sara Alexandra Valadas Da Silva Monteiro
-
Publication number: 20130281360Abstract: Arylomycin analogs are provided, wherein the analogs can have broad spectrum bioactivity. Resistance to the antibiotic bioactivity of natural product arylomycin in a range of pathogenic bacterial species has been found to depend upon single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases), wherein the presence of a proline residue confers arylomycin resistance. Arylomycin analogs are provided herein that can overcome that resistance and provide for a broader spectrum of antibiotic bioactivity than can natural product arylomycins such as arylomycin A2. Methods for determining if a bacterial strain is susceptible to narrow spectrum arylomycin antibiotics, or if a broad spectrum analog is required for treatment, is provided. Pharmaceutical compositions and methods of treatment of bacterial infections, and methods of synthesis of arylomycin analogs, are provided.Type: ApplicationFiled: August 31, 2011Publication date: October 24, 2013Applicant: The Scipps Research InstituteInventors: Floyd E. Romesberg, Peter A. Smith, Tucker C. Roberts
-
Publication number: 20130267458Abstract: Improved synthetic copolypeptide antimicrobials contain cationic amino acid residues and may be based on a blocky sequence. These antimicrobials show low mammalian toxicity and may undergo directed self-assembly. The inventive synthetic copolypeptides are useful in treatment of wounds and other infections.Type: ApplicationFiled: February 25, 2013Publication date: October 10, 2013Applicants: Amicrobe, Inc., The Regents of the University of CaliforniaInventors: Michael P. Bevilacqua, Diego Benitez, Timothy J. Deming, Jarrod A. Hanson, Lucas Koziol
-
Publication number: 20130252881Abstract: Decoy nucleic acid sequences comprising a sequence encoding all or part of a binding site for bacterial sigN alternative sigma54 factor are described. Uses of the decoys in antibacterial complexes and for the treatment of bacterial infections are also described.Type: ApplicationFiled: March 30, 2011Publication date: September 26, 2013Inventor: Michael McArthur
-
Publication number: 20130252882Abstract: This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.Type: ApplicationFiled: January 31, 2012Publication date: September 26, 2013Applicant: EVOLVA SAInventors: Jutta Heim, Peter Schneider, Patrick Roussel, Daniel Milligan, Christian Bartels, Glenn Dale
-
Publication number: 20130253382Abstract: Methods and compositions for the treatment of biofilms and/or the inhibition of biofilm formation. In one embodiment, a biofilm is treated and/or biofilm formation is inhibited by a method comprising contacting a biofilm or a surface with a bifunctional ligand comprising a quorum-sensing-peptide-binding region and a protease-binding region, whereby the biofilm is treated and/or biofilm formation on the surface is inhibited.Type: ApplicationFiled: March 15, 2013Publication date: September 26, 2013Inventors: RODOLFO ALARCON, Amy K. McNulty
-
Patent number: 8541364Abstract: The present invention is directed to the use of the peptide compound D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.Type: GrantFiled: September 9, 2008Date of Patent: September 24, 2013Assignee: Mondobiotech Laboratories AGInventors: Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher
-
Publication number: 20130243886Abstract: The present invention relates to the use of one or more compounds selected from the following classes of biologically active agents: an a-adrenergic antagonist, an anthelmintic agent, an antifungal agent, an antimalarial agent, an antineoplastic agent, an antipsychotic agent, an antioxidant, a vasodilator and/or a vitamin, or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection and in particular for killing multiplying, non-multiplying and/or clinically latent microorganisms associated with such an infection.Type: ApplicationFiled: September 9, 2011Publication date: September 19, 2013Applicant: HELPERBY THERAPEUTICS LIMITEDInventors: Yanmin Hu, Anthony RM Coates
-
Publication number: 20130231276Abstract: Bacterial multidrug resistance is attenuated in a subject by administering an aminoacyl-tRNA synthetase inhibitor and an antibacterial agent to the subject, wherein the aminoacyl-tRNA synthetase inhibitor is distinct from the antibacterial agent.Type: ApplicationFiled: April 12, 2013Publication date: September 5, 2013Applicant: Brown UniversityInventors: Jason K. Sello, James J. Vecchione
-
Publication number: 20130217619Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broad spectrum of antibiotic bioactivity. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: February 15, 2013Publication date: August 22, 2013Applicant: RQX PHARMACEUTICALS, INC.Inventor: RQX Pharmaceuticals, Inc.
-
Patent number: 8507650Abstract: The present invention provides compositions and methods for killing or suppressing growth of Gram-negative bacteria that infect, infest or cause disease in plants, including pathogenic, saprophytic and opportunistic microbes that cause disease in plants and food borne illness in people or in animal feed.Type: GrantFiled: June 4, 2012Date of Patent: August 13, 2013Assignees: Integrated Plant Genetics, Inc., University of Florida Research Foundation, Inc.Inventors: Dean W. Gabriel, Joseph D. Reddy
-
Publication number: 20130196900Abstract: The present invention provides compounds and compositions that enhance the innate immune system. The present invention comprises methods of preventing, treating or ameliorating an infectious disease comprising administering said compounds to a subject. The invention also comprises methods of formulation and administration of said compounds.Type: ApplicationFiled: January 18, 2013Publication date: August 1, 2013Applicant: MONTANA STATE UNIVERSITYInventor: MONTANA STATE UNIVERSITY
-
Publication number: 20130196901Abstract: Neisseria meningitidis PorA constructs are provided which have one or more disrupted variable regions created by insertion of entire conserved regions or conserved region amino acids. The highly immunogenic variable regions of PorA are responsible for eliciting strain-specific immune responses that are not broadly protective, so disruption of the variable regions directs the immune response against conserved region epitopes to effectively immunize against a broader spectrum of N. meningitidis strains. Also provided are encoding nucleic acids, genetic constructs, host cells expressing the PorA constructs and compositions, kits and methods for detection and treatment of Neisseria meningitidis infections.Type: ApplicationFiled: August 1, 2011Publication date: August 1, 2013Applicant: GRIFFITH UNIVERISTYInventors: Michael Paul Jennings, Ian Richard Anselm Peak
-
Publication number: 20130184201Abstract: The present invention is directed to cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity, preferably Kitastatin 1. The present invention is further directed to methods of inhibiting cancer cell growth and/or microbial growth in a host inflicted therewith by administering cyclodepsipeptide compounds to the inflicted host.Type: ApplicationFiled: March 6, 2013Publication date: July 18, 2013Applicants: Arizona State UniversityInventors: George R. Pettit, Rui Tan, Robin K. Pettit
-
Publication number: 20130178412Abstract: The invention relates to a S-(2,3-dihydroxypropyl)-cysteine peptide which has two long-chain fatty acids bonded in the form of esters at the dihydroxypropyl group, and which has the following sequence: (SEQ?ID?NO:?1) DhcGN?NDE?SNI?SFK?EK. The invention relates also to a composition comprising the mentioned peptide.Type: ApplicationFiled: September 16, 2008Publication date: July 11, 2013Inventor: Peter F. MUEHLRADT
-
Publication number: 20130157932Abstract: In some embodiments, the present invention is directed to compositions and methods for the treatment and prevention of urinary tract infections (UTIs) and urosepsis. In some embodiments, the methods of the invention comprise administering to a subject in need thereof a therapeutically effective amount of an agent that stimulates genito-urinary tract epithelial cells to produce NGAL, and/or an NGAL protein or a functional derivative thereof, and optionally also administering to the subject an additional agent useful for treating or preventing UTI or urosepsis. In other embodiments, the present invention also provides methods of screening for agents that stimulate urinary tract epithelial cells to produce NGAL.Type: ApplicationFiled: November 7, 2012Publication date: June 20, 2013Applicant: The Trustees of Columbia University in the City of New YorkInventors: The Trustees of Columbia University in the City of New York, Jonathan Barasch, Neal Paragas
-
Publication number: 20130150286Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.Type: ApplicationFiled: June 25, 2010Publication date: June 13, 2013Inventors: Jean-Claude Sirard, Jose A. Chabalgoity
-
Publication number: 20130129682Abstract: The present invention provides isolated polypeptides having oligopeptide permease activity and an amino acid sequence that has at least 80% identity with a Haemophilus parasuis OppA polypeptide. Also provided by the present invention are isolated polynucleotides that encode the polypeptides described herein, and antibody that specifically binds a polypeptide described herein. The present invention further provides genetically modified microbes, such as attenuated Haemophilus parasuis strains and other microbes that express polypeptides described herein. Also included are methods for using the polypeptides, polynucleotides, antibody, and genetically modified microbes.Type: ApplicationFiled: November 4, 2010Publication date: May 23, 2013Applicant: Regents of the University of MinnesotaInventor: Simone Oliveira
-
Patent number: 8440207Abstract: A live bacterium, having a DNA construct stabilized against transduction of other bacteria, having a promoter sequence and encoding a fusion peptide, comprising a bacterial secretion peptide portion and a non-bacterial immunogenic polypeptide portion, having a nucleotide sequence coding for the non-bacterial immunogenic polypeptide portion which has at least one codon optimized for bacterial expression. The bacterium has a secretion mechanism which interacts with at least the bacterial secretion peptide portion to cause a secretion of the fusion peptide from the bacterium, and a genetic virulence attenuating mutation. The bacterium is adapted to act as an animal vaccine, to transiently infect a tissue of the animal, and cause an immunity response to the non-bacterial immunogenic polypeptide portion in the animal to a non-bacterial organism associated with the non-bacterial immunogenic polypeptide portion.Type: GrantFiled: February 9, 2012Date of Patent: May 14, 2013Assignee: Aviex Technologies, LLCInventor: David Gordon Bermudes
-
Publication number: 20130115170Abstract: Compositions and methods relating to interfering with the interaction of gangliosides, such as GM1, with their ligands are provided. For example, methods are provided for treating infections by blocking the infectious agent from binding with GM1 using GM1-like peptides. Also provided are methods of inhibiting ligands from binding to GM 1 on the surface of cells and for neutralizing anti-GM1 antibodies in neurological diseases.Type: ApplicationFiled: October 19, 2012Publication date: May 9, 2013Inventors: Robert Yu, Han-Chung Wu, Seigo Usuki
-
Publication number: 20130116168Abstract: The invention relates to a composition comprising pea protein hydrolysate for the treatment and/or prevention of infection by gastrointestinal pathogens, in particular Helicobacter pylori and/or a disease associated with infection by said gastrointestinal pathogen in mammals.Type: ApplicationFiled: March 29, 2011Publication date: May 9, 2013Inventors: Gilda Elise Georgi, Marco Euler, Marko Mank, Andreas Hensel, Michael Niehues, Monika Klapperich, Bernd Stahl
-
Publication number: 20130108575Abstract: This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.Type: ApplicationFiled: October 16, 2012Publication date: May 2, 2013Applicant: C3 JIAN, INC.Inventor: C3 Jian, Inc.
-
Publication number: 20130109616Abstract: A method is provided for isolating protease resistant antimicrobial peptides (AMPs) from a peptide display library. A plurality of nucleic acid constructs that encode displayed peptides are expressed, resulting in the formation of a plurality of peptide-nucleic acid complexes, each complex comprising at least one displayed peptide associated with the corresponding nucleic acid construct encoding the displayed peptide. The complexes are exposed to at least one protease, to allow the proteolysis of protease-sensitive peptides, such that resistant peptides remain. The peptide-nucleic acid complexes are further exposed to a membrane composition to allow association of complexes that contain membrane-associating peptides. Complexes that remain unassociated with the membrane are removed; and membrane-associated complexes are recovered. The AMPs so characterised may be resistant to one or more protease enzymes and exhibit antimicrobial activity against one or more microbe.Type: ApplicationFiled: January 11, 2011Publication date: May 2, 2013Applicant: ISOGENICA LTDInventors: William Eldridge, Christopher Ullman, Marc Alan Fox, David Okhono Ulaeto, Joanne Elizabeth Thwaite
-
Publication number: 20130102524Abstract: The present invention relates to peptides and their use in the treatment of microbial infections, in particular bacterial infections. In particular, the invention relates to peptides wherein at least 75% of the amino acids of the peptide are arginine and phenylalanine amino acids, at least 50% of the amino acids being arginine amino acids and at least 15% of the amino acids being phenylalanine amino acids.Type: ApplicationFiled: March 30, 2011Publication date: April 25, 2013Applicant: Novabiotics LimitedInventors: Deborah O'Neil, Derry Mercer, Cedric Charrier
-
Patent number: 8426366Abstract: Provided are methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. Also provided are specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.Type: GrantFiled: April 29, 2012Date of Patent: April 23, 2013Inventor: Yitzchak Hillman
-
Publication number: 20130096049Abstract: The invention concerns a novel antimicrobial peptide (AMP) polymer conjugate comprising at least one AMP, typically colistin, and a dextrin polymer wherein said dextrin polymer has a molecular weight between 5,000-60,000 g/mol and is modified by the additions of pendant groups which increase the stability of the conjugate and so delays its degradation thereby slowing the rate at which the AMP is released.Type: ApplicationFiled: June 1, 2011Publication date: April 18, 2013Applicant: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITEDInventors: Elaine Ferguson, David Thomas, Timothy Walsh
-
Patent number: 8415294Abstract: The present invention is directed to cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity, preferably Kitastatin 1. The present invention is further directed to methods of inhibiting cancer cell growth and/or microbial growth in a host inflicted therewith by administering cyclodepsipeptide compounds to the inflicted host.Type: GrantFiled: June 5, 2008Date of Patent: April 9, 2013Assignee: Arizona Board of RegentsInventors: George R. Pettit, Rui Tan, Robin K. Pettit
-
Patent number: 8415307Abstract: Provided herein are novel compounds and novel protected compounds that can be derived from polymyxin, including, e.g., polymyxin A. The novel compounds have antibacterial properties against a diverse range of Gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin A. Also provided are antibacterial pharmaceutical compositions containing the novel compounds and novel protected compounds, as well as methods for preparing the antibacterial compounds and protected compounds.Type: GrantFiled: June 23, 2011Date of Patent: April 9, 2013Assignees: BioSource Pharm, Inc., Cubist Pharmaceuticals, Inc.Inventors: William V. Curran, Christopher M. Liu, Amy C. D. Bombardier, Richard A. Leese, You Seok Hwang, Blaise S. Lippa, Yanzhi Zhang
-
Publication number: 20130072423Abstract: The present invention relates to the use of peptide compounds for the prevention and/or treatment of a bacterial infection.Type: ApplicationFiled: November 9, 2012Publication date: March 21, 2013Applicant: KARLSRUHER INSTITUT FUR TECHNOLOGIEInventor: Karlsruher Institut fur Technologie
-
Publication number: 20130053305Abstract: Compounds of formula (I), where: R0 is (C8-C11)-branched alkyl, CH3—(CH2)m—, CH3—O—(CH2CH2O)2CH2—, or phenyl-(CH2)x—; m=6-10; x=1-3; R1, R3, R4, R7, and R8 are independently selected from the formula GF-(CH2)n—; with n=1-4; and GF=—NH2 or —NH—C(?NH)—NH2; R2 is —CH(CH3)(OH), —CH(CH3)2, —CH2NH2 o —CH2OH; R5 and R6 are independently selected among H, —(C1-C4)— linear or branched alkyl, —(CH2)—R10, —CH2—CH2—S—CH3 and —CH—(CH3)—OH; R9 is CONH2, —CH(CH3)(OH) or CONHR11; R10 is phenyl, 3-indolyl, 4-imidazolyl, 4-hydroyiphenyl, ? o ?-naphtyl or 2-, 3- or 4-pyridyl; R11 is a specific peptide sequence; u is CH2 or S; v is NH o S; w is CH2 or CO; with the condition that when R9 is CONH2, then (a) R5 or R6 is —CH(CH3)(OH), or (b) R5 and R6 are H; or (c) the configuration of the C bound to R9 is S or (d) the configuration of the C bound to R5 is R; and with the condition that when R9 is —CH(CH3)OH, then R8 is GF(CH2)n where n is 3 and GF is —NH—C(?NH)—NH2, and R7 is GF(CH2)n where n is 2 and GF is NH2, have been found toType: ApplicationFiled: March 9, 2011Publication date: February 28, 2013Applicant: UNIVERSIDAD DE BARCELONAInventors: Francesc Rabanal Anglada, Yolanda Cajal Visa, Maria Garcia Subirats, Montserrat Rodrígues Núñez
-
Publication number: 20130052182Abstract: The present invention relates to methods of eliminating, reducing or preventing bacterial biofilms by means of a fusion protein comprising an endolysin, an autolysin or a bacteriocin to which a peptide with membrane or LPS disrupting activity is fused. Further, the present invention relates to fusion proteins for use as a medicament, in particular for the treatment or prevention of Gram-negative and/or Gram-positive bacterial infections associated with bacterial biofilm, as diagnostic means, disinfectant or as cosmetic substance. The present invention also relates to the removal or reduction or prevention of Gram-negative and/or Gram-positive bacterial contamination associated with bacterial biofilm of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.Type: ApplicationFiled: April 27, 2011Publication date: February 28, 2013Applicant: LYSANDO AGInventor: Stefan Miller
-
Publication number: 20130028939Abstract: The invention relates to a nucleic acid molecule selected from the group comprising a) a nucleic acid molecule having one of the nucleotide sequences presented in SEQ ID:NO 4 to SEQ ID:NO 8, b) a nucleic acid molecule that codes for a peptide having one of the amino acid sequences presented in SEQ ID:NO 12 to SEQ ID:NO 16, c) a nucleic acid molecule, the complementary strand of which hybridizes to a nucleic acid molecule according to a) or b) and which codes for a peptide having antimicrobial activity, and d) a nucleic acid molecule, the nucleotide sequence of which deviates from the nucleotide sequence of a nucleic acid molecule according to c) because of the degenerated genetic code.Type: ApplicationFiled: November 20, 2010Publication date: January 31, 2013Applicant: CHRISTIAN-ALBRECHTS-UNIVERSITAT ZU KIELInventor: Joachim Grötzinger
-
Patent number: 8354246Abstract: The invention provides a method of inhibiting a bacterial RNA polymerases. The invention has applications in control of bacterial RNA polymerase activity, control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, and antibacterial therapy.Type: GrantFiled: December 18, 2009Date of Patent: January 15, 2013Assignee: Rutgers, The State University of New JerseyInventors: Richard H. Ebright, Jayanta Mukhopadhyay, Konstantin Severinov, Ekaterina Semenova
-
Patent number: 8343912Abstract: Provided herein is an antibacterial compound of the following formula: or a pharmaceutically acceptable salt thereof. The antibacterial compound has antibacterial properties against a diverse range of gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin B. Also provided are antibacterial pharmaceutical compositions containing the antibacterial compound, as well as methods for preparing the antibacterial compound.Type: GrantFiled: December 22, 2009Date of Patent: January 1, 2013Assignee: Biosource Pharm, Inc.Inventor: Richard A. Leese
-
Publication number: 20120328684Abstract: Provided herein are methods for treating planktonic bacteria or a biofilm. The methods include contacting the planktonic bacteria or biofilm with an effective amount of an isolated Citrobacter freundii colicin A polypeptide, wherein the polypeptide has an antibacterial activity against the planktonic bacteria or the biofilm. Methods are also provided herein for treating a subject that has a bacterial infection, for example caused by a biofilm. The methods can be used to treat a biofilm on a living or non-living surface. Also provided herein are Citrobacter freundii colicin A polypeptides that have an antibacterial activity against planktonic bacteria or surface attached bacteria, and nucleic acid sequences encoding the polypeptides. Medical devices comprising a surface having an antimicrobial effective amount of a Citrobacter freundii colicin A polypeptide, or a nucleic acid molecule encoding the polypeptide, are also disclosed.Type: ApplicationFiled: June 20, 2012Publication date: December 27, 2012Inventors: Robert M.Q. Shanks, Daniel E. Kadouri
-
Publication number: 20120328568Abstract: The disclosure relates to uses of a purified or isolated lectin to kill bacteria, viruses, and other pathogens. In certain embodiments, the disclosure relates to method of treating or preventing an infection comprising administering a purified or isolated galectin to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, or diagnosed with a pathogenic infection.Type: ApplicationFiled: February 11, 2011Publication date: December 27, 2012Applicant: EMORY UNIVERSITYInventors: Richard D Cummings, Sean R. Stowell, Connie Arthur
-
Publication number: 20120316105Abstract: The present invention provides a new class of polymyxin derivates useful for treating bacterial infections, especially Gram-negative infections, that have reduced renal cytotoxicity.Type: ApplicationFiled: June 7, 2012Publication date: December 13, 2012Inventors: Thomas Victor Magee, Jinshan Michael Chen, Carlos Alberto Martinez, Zhengong B. Li
-
Publication number: 20120316103Abstract: The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections.Type: ApplicationFiled: August 22, 2012Publication date: December 13, 2012Applicant: NOVABIOTICS LIMITEDInventor: Deborah O'NEIL
-
Publication number: 20120316104Abstract: The present invention provides compositions and methods for killing or suppressing growth of Gram-negative bacteria that infect, infest or cause disease in plants, including pathogenic, saprophytic and opportunistic microbes that cause disease in plants and food borne illness in people or in animal feed.Type: ApplicationFiled: June 4, 2012Publication date: December 13, 2012Applicants: Unviersity of Florida Research Foundation, Inc., Integrated Plant Genetics, Inc.Inventors: Dean W. GABRIEL, Joseph D. Reddy
-
Patent number: 8329645Abstract: The present invention relates to a polymyxin derivative wherein R1, R2 and R3 are optional and R1, R2, R3, R5, R8 and R9 are cationic or neutral amino acid residues selected so that the total number of positive charges at physiological pH is at least two but no more than three; and to a combination product comprising at least two such derivatives.Type: GrantFiled: February 5, 2009Date of Patent: December 11, 2012Assignee: Northern Antibiotics Ltd.Inventors: Martti Sakari Vaara, Timo Ilmari Vaara
-
Publication number: 20120308638Abstract: The present invention provides novel therapeutic antimicrobial peptides that are bactericides and have an inhibitory effect on biofilms produced by biofilm-forming bacteria and especially biofilm-forming staphyloccocal bacteria. The invention includes the nucleic acids encoding the polypeptides, methods of treating bacterial infections, medical devices or implants or prosthetics impregnated with, covered or coated in the polypeptides, and means of delivery of the peptide to the oral cavity.Type: ApplicationFiled: December 16, 2010Publication date: December 6, 2012Inventors: Mathew Upton, Stephanie Sandiford
-
Publication number: 20120295839Abstract: Methods of treatment or prophylaxis of bacterial vaginosis, prevention of recurrence of bacterial vaginosis and alleviation or prevention of symptoms or diagnostic criteria of bacterial vaginosis are provided. The methods include administration of an effective amount of a macromolecule comprising a polylysine, polyamidoamine, poly(etherhydroxyamine) or poly(propyleneimine) dendrimer and one or more sulfonic acid containing moieties attached thereto.Type: ApplicationFiled: May 16, 2012Publication date: November 22, 2012Applicant: STARPHARMA PTY LIMITEDInventors: Jeremy Robert Arthur Paull, Jacinth Kincaid Fairley, Clare Frances Price, Gareth Rhys Lewis